Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: denosumab

Denosumab Dosing Delays Tied to Increased Fracture Risk

Megan Brooks  |  July 27, 2020

NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabfracture riskFracturesOsteoporosisosteoporosis treatments

Zoledronate After Denosumab Does Not Fully Prevent Bone Loss

Marilynn Larkin  |  June 23, 2020

NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone lossbone mineral density (BMD)denosumabOsteoporosisosteoporosis treatmentszoledronate

Denosumab Tied to Infection Risk

Marilynn Larkin  |  January 13, 2020

NEW YORK (Reuters Health)—The osteoporosis drug denosumab is associated with a higher incidence of serious infections compared with placebo, but the risk is similar to comparator drugs, a systematic review and meta-analysis reveals. Talia Diker-Cohen, MD, PhD, of Tel Aviv University, and colleagues searched the literature through May 2019 for randomized controlled trials of denosumab…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesdenosumabInfectionOsteoporosis

High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

Anne Harding  |  September 9, 2019

NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabOsteoporosisosteoporosis treatmentsteriparatideteriparatide treatment for osteoporosis

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

Megan Brooks  |  April 25, 2019

NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:alendronatedenosumabFracturesOsteoporosisosteoporosis treatmentsosteoporotic fracture rates

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  June 11, 2018

Denosumab is now approved to treat adults with glucocorticoid-induced osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabFDAGlucocorticoid-Induced OsteoporosisOsteoporosisosteoporosis treatmentsU.S. Food and Drug Administration (FDA)

Denosumab Is Effective for Glucocorticoid-Induced Osteoporosis

Lara C. Pullen, PhD  |  May 15, 2018

A study identified denosumab as a useful treatment for patients initiating or continuing glucocorticoids who are at risk for fractures. Denosumab had clinical effects similar to risedronate but was more effective than risedronate in the improvement of bone mineral density at the lumbar spine…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesdenosumabGlucocorticoid-Induced OsteoporosisOsteoporosisosteoporosis treatmentsrisedronate

Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis

Reuters Staff  |  April 26, 2018

NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesbone mineral density (BMD)denosumabGlucocorticoidsOsteoporosisosteoporosis treatmentsrisedronate

Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis

Marilynn Larkin  |  March 28, 2018

NEW YORK (Reuters Health)—After discontinuation of teriparatide, increases in bone mineral density (BMD) are greater with denosumab than with zoledronic acid, but whether that translates into a decreased fragility fracture risk remains unknown, researchers say. Teriparatide was the first anabolic treatment approved for osteoporosis in the U.S. It has been shown to increase BMD, and…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabOsteoporosisosteoporosis treatmentsteriparatide treatment for osteoporosis

Supplemental Application for Denosumab Goes to FDA

Michele B. Kaufman, PharmD, BCGP  |  October 25, 2017

The FDA accepted for review a supplemental biologics license application for denosumab to treat patients with glucocorticoid-induced osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabFDAGlucocorticoid-Induced OsteoporosisOsteoporosisU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences